Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | AB680 |
Synonyms | |
Therapy Description |
AB680 is an inhibitor that selectively targets CD73, resulting in decreased production of extracellular adenosine (ADO), and potentially leading to decreased ADO-mediated T-cell suppression and improved anti-tumor immunity (Cancer Res 2018;78(13 Suppl):Abstract nr 1756, PMID: 32614585). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
AB680 | AB-680|AB 680|quemliclustat | Adenosine Targeting 23 CD73 Antibody 12 | AB680 is an inhibitor that selectively targets CD73, resulting in decreased production of extracellular adenosine (ADO), and potentially leading to decreased ADO-mediated T-cell suppression and improved anti-tumor immunity (Cancer Res 2018;78(13 Suppl):Abstract nr 1756, PMID: 32614585). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|